Edgar Filing: UROPLASTY INC - Form 8-K

UROPLASTY INC Form 8-K November 10, 2008

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: November 10, 2008

UROPLASTY, INC.

(Exact name of registrant as specified in charter)

000-20989 41-1719250

(Commission File No.)

(IRS Employer Identification No.)

Minnesota

(State or other jurisdiction of incorporation or organization)

5420 Feltl Road

Minnetonka, Minnesota 55343

(Address of principal executive offices)

952-426-6140

(Registrant s telephone number, including area code)

Not Applicable

(Former Name and Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 of the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Table of Contents 2

Edgar Filing: UROPLASTY INC - Form 8-K

TABLE OF CONTENTS

Item 7.01 Regulation FD Disclosure

Item 9.01 Financial Statements and Exhibits.

Signatures EXHIBIT 99.1 Edgar Filing: UROPLASTY INC - Form 8-K

Table of Contents

Item 7.01 Regulation FD Disclosure

The following forward-looking statements are subject to risks and uncertainties. We may not meet our expectations set out below for business and financial reasons. In addition to the specific risks described below, we recommend that you carefully consider the risk factors described in our other SEC filings in evaluating us.

Investor Conference Presentation. We intend to present certain financial projections and other information to certain potential investors and analysts in connection with our presentation on November 10, 2008 at an investor conference sponsored by Rodman & Renshaw. A copy of the presentation we intend to present at the conference is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. We may not achieve our projected financial performance, and, in fact, by publicly announcing these projections, our stock price may decline if we do not achieve these financial milestones.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit No. Description

99.1 Investor Conference Presentation (furnished herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 10, 2008

UROPLASTY, INC.

By: /s/ Mahedi A. Jiwani Mahedi A. Jiwani Vice President, Chief Financial Officer and Treasurer

Table of Contents 4